These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

307 related items for PubMed ID: 20977576

  • 21. Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus.
    Bosi E, Dotta F, Jia Y, Goodman M.
    Diabetes Obes Metab; 2009 May; 11(5):506-15. PubMed ID: 19320662
    [Abstract] [Full Text] [Related]

  • 22. [Metabolic control and weight loss in patients with obesity and type 2 diabetes mellitus, treated with exenatide].
    Pujante Alarcón P, Hellín Gil MD, Román LM, Ferrer Gómez M, García Zafra MV, Tébar Massó J.
    Med Clin (Barc); 2012 Dec 01; 139(13):572-8. PubMed ID: 22209597
    [Abstract] [Full Text] [Related]

  • 23. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea.
    Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, Baron AD.
    Diabetes Care; 2005 May 01; 28(5):1083-91. PubMed ID: 15855571
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study.
    Owens DR, Swallow R, Dugi KA, Woerle HJ.
    Diabet Med; 2011 Nov 01; 28(11):1352-61. PubMed ID: 21781152
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial.
    Diamant M, Van Gaal L, Stranks S, Northrup J, Cao D, Taylor K, Trautmann M.
    Lancet; 2010 Jun 26; 375(9733):2234-43. PubMed ID: 20609969
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Pioglitazone is effective therapy for elderly patients with type 2 diabetes mellitus.
    Rajagopalan R, Perez A, Ye Z, Khan M, Murray FT.
    Drugs Aging; 2004 Jun 26; 21(4):259-71. PubMed ID: 15012171
    [Abstract] [Full Text] [Related]

  • 34. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes.
    Fineman MS, Bicsak TA, Shen LZ, Taylor K, Gaines E, Varns A, Kim D, Baron AD.
    Diabetes Care; 2003 Aug 26; 26(8):2370-7. PubMed ID: 12882864
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Safety and efficacy of twice-daily exenatide in Taiwanese patients with inadequately controlled type 2 diabetes mellitus.
    Lu CH, Wu TJ, Shih KC, Ni E, Reed V, Yu M, Sheu WH, Chuang LM.
    J Formos Med Assoc; 2013 Mar 26; 112(3):144-50. PubMed ID: 23473527
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.